Back to Durvalumab

Durvalumab

Showing 5 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Kievit et al.	2023	Prospective	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial	10.1016/j.lungcan.2023.02.004	—	3	60	10	Lung cancer	any	Anti-PD-(L)1 mAb	Durvalumab	—	3	extra-cranial	lung	—	20	20	20	1	1	1	20	20	20	Treatment-rel.	0	—	—	0	0	—	—
Pouessel et al.	2023	Prospective	Hypofractionated Stereotactic Re-irradiation and	10.1093/oncolo/oyad095	NCT02866747	6	65	12	brain	oligometastatic	Anti-PD-(L)1 mAb	Durvalumab	—	6	intra-cranial	brain	—	24	24	24	3	3	3	8	8	8	Treatment-rel.	—	—	2	any G3: 6 AEs	any G3: 2 pts	any G3: Vestibular neuritis, cerebellar syndrome, intracranial hypertension, fatigue, lung tuberculosis, aseptic lymphocytic meningitis	unknown
Wu et al.	2023	Prospective	Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer	10.1016/j.ijrobp.2023.03.069	NCT03148327	18	79	36	Lung cancer	primary	Anti-PD-(L)1 mAb	Durvalumab	—	18	extra-cranial	lung	—	54	50	65	3	3	10	18	6.5	18	Treatment-rel.	2	5	—	acute G3: 3 AEs, late G3: 7 AEs, late G4: 1 AE, late G5: 1 AE	acute G3: 2 pts, late G3: 3 pts, late G4: 1 pt, late G5: 1 pt	acute G3: pneumonitis, late G3: pneumonitis, sepsis, unstable angina, atrial fibrillation, heart failure, late G4: respiratory failure, late G5: death from respiratory failure	unknown
Xie et al.	2021	Prospective	Correction: Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	10.1158/1078-0432.Ccr-20-4640	NCT02311361	24	Missing	Missing	pancreas	oligometastatic, metastatic	Anti-PD-(L)1 mAb	Durvalumab	—	Missing	extra-cranial	other	abdominal, thoracic	Missing	8	25	Missing	1	5	Missing	5	8	Treatment-rel.	—	—	4	any G3-4: unknown	any G3-4: 4 pts	any G3-4: lymphocyte count decrased	—
Levy et al.	2016	Retrospective	Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial	10.1016/j.ejca.2016.09.013	NCT01693562	10	Missing	Missing	Missing	metastatic	Anti-PD-(L)1 mAb	Durvalumab	—	3	intra-cranial	brain	—	84	78	92	2	1	3	Missing	Missing	Missing	RT-related	0	0	0	0	0	—	—